BioIncept LLC develops compound for embryo development in humans by promoting implantation and trophoblast invasion. One of the firm's primary developments is PreImplantation Factor, a human peptide secreted by 2 cell embryos. PIF enables selective regulation of the immune system to accept the embryo while maintaining protection against disease and is targeted to treat immune and pregnancy disorders, and transplant rejection.
